Categories: Tech

Columbus Weekly report on share buyback

Company announcement no. 39/2025

Transactions in the period 8 December 2025 to 12 December 2025
On 30 June 2025, Columbus A/S announced a share buyback programme under which the company will repurchase shares for up to DKK 16m during the period from 30 June 2025 to 11 March 2026, both dates included, as outlined in company announcement no. 8/2025.

The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buyback programme in the period 8 December 2025 to 12 December 2025:

Number of shares bought Average purchase price (DKK) Transaction value (DKK)
Accumulated, last announcement 1,099,136 10.04 11,029,839.26
8 December 2025 7,000 9.72 68,019.70
9 December 2025 3,500 9.88 34,580.00
10 December 2025 7,000 9.72 68,040.00
11 December 2025 7,000 9.81 68,658.80
12 December 2025 7,000 9.70 67,919.60
Total, 8 December 2025 to 12 December 2025 31,500 9.75 307,218.10
Total accumulated under the programme 1,130,636 10.03 11,337,057.36

With the transactions stated above, Columbus A/S holds a total of 1,130,636 own shares, corresponding to 0.87% of the Company’s share capital.

For further information, please contact:
CFO, Brian Iversen, +45 70 20 50 00

GlobeNews Wire

Recent Posts

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

2 days ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

1 week ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

1 week ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

4 weeks ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans…

1 month ago